Affiliation:
1. Department of Medicine, School of Clinical Medicine The University of Hong Kong Hong Kong
2. State Key Laboratory of Liver Research The University of Hong Kong Hong Kong
Abstract
AbstractBackground and AimSpontaneous seroclearance of hepatitis B surface antigen (HBsAg) is a rare event that occurs in patients that are chronically infected with the hepatitis B virus. As the functional cure and ultimate treatment endpoint of chronic hepatitis B (CHB), HBsAg seroclearance is an important milestone in the natural history of CHB and serves great clinical value. This study aims to identify host and viral factors associated with HBsAg seroclearance.MethodsThis is a retrospective study carried out in the Queen Mary Hospital, Hong Kong. By analyzing the plasma retrieved from the serum archive (collected during 2011–2021) of 100 CHB patients attending the hospital's liver clinic, the longitudinal cytokine profiles between the HBsAg‐losers and the control groups were compared.ResultsData revealed that plasma levels of IP‐10 were significantly lower at 3–5 years prior to HBsAg seroclearance compared with patients who remained HBsAg positive (P < 0.05). Receiver operating characteristic curve analysis reveals that plasma IP‐10 levels at multiple time points before HBsAg seroclearance return area under receivor‐operating characteristic curve (AUC) greater than 0.7. Plasma IP‐10 levels at 42.39 pg/mL produced an AUC = 0.723 with 74.0% sensitivity and 75.5% specificity to predict subsequent HBsAg seroclearance in the next 3–5 years. Low plasma IP‐10 identified 91.4% patients with quantitative HBsAg < 100 IU/mL who would subsequently develop HBsAg seroclearance, compared with 37% with higher plasma IP‐10 levels (P < 0.001).ConclusionsLow plasma levels of IP‐10 are associated with subsequent HBsAg seroclearance, suggesting potential clinical utilities of measurement of IP‐10 in predicting HBsAg seroclearance, especially among patients with low HBsAg.
Funder
Lo Ying Shek Chi Wai Foundation
Subject
Gastroenterology,Hepatology
Reference41 articles.
1. WHO.World Health Organization factsheets for chronic hepatitis B: WHO;2021[updated 27 July 2020. Available from:https://www.who.int/news‐room/fact‐sheets/detail/hepatitis‐b
2. HBsAg Seroclearance in Chronic Hepatitis B in Asian Patients: Replicative Level and Risk of Hepatocellular Carcinoma
3. Factors Associated With Rates of HBsAg Seroclearance in Adults With Chronic HBV Infection: A Systematic Review and Meta-analysis
4. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection
5. Factors associated with natural seroclearance of hepatitis B surface antigen and prognosis after seroclearance: a prospective follow‐up study;Kim JH;Hepatogastroenterology,2008